Clinical Trial Update: A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

View source ↗

Summary

This document reports a post-approval commitment study of Capmatinib (Tabrecta) in South Korea, currently recruiting for Non-Small Cell Lung Cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tabrecta (Capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small-Cell Lung Carcinoma | Status: RECRUITING